Avanti Biosciences is developing ABI-171, an oral precision kinase inhibitor designed to reverse—not just slow—the progression of idiopathic pulmonary fibrosis (IPF). The IND-ready asset has received FDA Orphan Drug Designation and is supported by preclinical data showing functional improvements and head-to-head comparisons against current standard of care. Phase 1 clinical trials are targeted to begin in the second half of 2026.
Funding
Funding not disclosed
Founders
Product
Problem
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease affecting over 150,000 adults in the United States, yet every approved therapy only slows the decline in lung function. None of the existing treatments reverse the underlying fibrotic process, leaving patients with a relentless loss of respiratory capacity and no path to recovery.
Solution
Avanti Biosciences is advancing ABI-171, an oral precision kinase inhibitor designed to reverse fibrosis rather than merely slow its progression. The compound has completed FDA Pre-IND meetings and holds Orphan Drug Designation, with a comprehensive preclinical package that includes human fibroblast mechanistic validation and functional in vivo endpoints. Head-to-head studies against current standard of care demonstrate ABI-171's potential to meaningfully alter disease trajectory. The program is IND-ready, with Phase 1 initiation targeted for the second half of 2026, positioning the company to bring a disease-modifying therapy to patients who currently have no option that reverses their condition.
Target Audience
Primary customers are pulmonologists and hepatologists treating patients with IPF and NASH-associated liver fibrosis, as well as biopharmaceutical partners seeking late-stage licensing or co-development opportunities.
Features
- Oral precision kinase inhibitor specifically designed to reverse fibrotic tissue remodeling in IPF and NASH-associated liver fibrosis
- FDA Orphan Drug Designation, providing development incentives and potential market exclusivity
- IND-ready status supported by a comprehensive preclinical package including human fibroblast mechanistic validation
- Functional in vivo efficacy endpoints demonstrated in head-to-head comparisons with current standard of care
- Backed by over $7M in NIH non-dilutive funding, including a recent NIDDK SBIR grant supporting translational development